{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-068599","form_type":"8-K","ticker":"MBX","cik":"0001776111","company_name":"MBX Biosciences, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.672961+00:00","generated_at":"2026-05-22T00:05:41.014241+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MBX Biosciences Q1 net loss $23.9M; cash $240.8M; Phase 2 canvuparatide data due 3Q25","bullets":["Net loss $23.9M (vs $12.3M YoY); R&D $22.4M (up 103% YoY) on MBX 4291 and canvuparatide trials.","Cash, cash equivalents & marketable securities $240.8M; expected to fund operations into mid-2027.","Phase 2 Avail topline results for canvuparatide in hypoparathyroidism expected in 3Q 2025.","IND submission for MBX 4291 (GLP-1/GIP co-agonist for obesity) on track for Q2 2025.","Phase 2 trial for MBX 1416 in post-bariatric hypoglycemia expected to start H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-068599","json":"https://secwatch.observer/filing/0000950170-25-068599.json","markdown":"https://secwatch.observer/filing/0000950170-25-068599.md","text":"https://secwatch.observer/filing/0000950170-25-068599.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025068599/0000950170-25-068599-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025068599/mbx-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:05:41.014241+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}